What is the revenue and EPS growth rate for UFP Technologies year over year?

What is the market's earnings forecast for UFP Technologies next quarter?

Did UFP Technologies beat or miss consensus estimates last quarter?

What is UFP Technologies's latest dividend and current dividend yield?

What were the key takeaways from UFP Technologies's earnings call?

What factors drove the changes in UFP Technologies's revenue and profit?

What is UFP Technologies's gross profit margin?

What guidance did UFP Technologies's management provide for the next earnings period?

- **Revenue milestone**: $602.8M (+19.5% YoY), EPS +15.4% despite AJR challenges.\n- **Strategic expansion**: 6th DR facility, program transfers, and new contracts.\n- **Financial resilience**: 17.1% operating margin, strong cash flow, and cybersecurity recovery.\n- **Growth drivers**: Safe patient handling (+double-digit), robotic surgery, and infection prevention launches.\n- **AJR progress**: Q4 inefficiency down to $1.2M, Q1 impact diminishing.

**【CEO Summary】
- Full-year revenue reached $602.8 million, up 19.5% YoY, with EPS growing 15.4% despite $6.3 million in AJR labor inefficiencies.\n- Strategic initiatives include contract extensions, facility expansions (e.g., 6th building in La Romana), and program launches in infection prevention and robotic surgery.\n- CEO transition to Mitch Rock in June, with Jeff Bailly remaining as Executive Chair to support strategic acquisitions.\n\n**【CFO Financial Commentary】**\n- GAAP net income: $420 million; Non-GAAP EPS: $1.08, exceeding expectations.\n- Gross margin 28.3% (28.2% YoY), improving to 29.3% excluding AJR costs.\n- Strong cash flow ($92M) and debt reduction ($53.9M), ending with leverage ratio 1.1x.\n- Cybersecurity incident resolved with minimal operational impact, backed by insurance.\n\n**Q&A Highlights】**\n- Contract extension with largest customer includes volume increases and cost-sharing provisions.\n- AJR inefficiencies reduced to $1.2M in Q4, with Q1 impact expected to decline.\n- New programs launched in infection prevention and robotic surgery, with 3 programs transferring to DR.\n- Safe patient handling market growing double-digit YoY.\n- Backlog remains, but gradual resolution expected in 2026.

UFP Technologies, Inc.(UFPT)-20260225-2025 Q4 Earnings call transcript

- **MedTech Growth Accelerates**: Interventional, Orthopedics, Wound Care segments grow >30% YoY, offsetting 23% decline in legacy AJR business.
- **Robotic Surgery Expansion**: 2026+ pipeline of $10M+ programs, with largest customer requesting 4-year contract extension requiring $M+ capital investments.
- **AJR Facility Turnaround**: Q3 labor inefficiency costs reduced to $3M (from $16M Q2), with Q4 2025 expected to reduce $8M backlog.
- **Acquisition Momentum**: 15-month M&A pipeline delivers $9M+ inorganic growth, with 2026 focus on MedTech adjacencies.
- **Financial Resilience**: 2025 GAAP net income $420M, Non-GAAP EPS $1.08, with leverage ratio <1.5x.

**Core Details - Detail Page**

**Management Opening Remarks**
- CEO Jeff Bailly highlighted Q3 2025 organic sales growth of 6.5% to $154.6M, driven by MedTech segments (Interventional, Orthopedics, Wound Care) growing >30% YoY. However, Patient Services & Support (AJR/Stryker business) declined 23% due to labor inefficiency at AJR Illinois facility.
- Advanced Components (non-MedTech) declined 2.7% as company refocused resources on MedTech.
- Q3 revenue was $154.6M, with MedTech businesses growing 7.3% YoY.

**CEO Commentary**
- **Robotic Surgery Growth**: Q3 robotic surgery revenue +5.1%, with 2 new programs expected to contribute >$10M in 2026. Largest customer requested multi-year contract extension requiring $M+ capital investments in Dominican Republic facilities.
- **AJR Facility Recovery**: Q3 labor inefficiency reduced to $3M incremental costs (from $16M in Q2). September marked return to profitability, with Q4 expected to improve further.
- **Acquisition Performance**: 15-month M&A pipeline delivered $9M+ inorganic growth, with 2025 acquisitions (UNIPEC, TPI) immediately accretive.
- **Backlog Management**: $16M unfilled orders due to AJR inefficiency, expected to ramp up capacity in Q4 2025.

**CFO Financial Commentary**
- **GAAP Metrics**: Q3 2025 GAAP net income $420M, Non-GAAP EPS $1.08 (vs. $0.95 consensus). 
- **Gross Margin**: 27.7% (down 300bps YoY due to AJR inefficiency). 
- **Liquidity**: $35.9M cash from operations, $17.5M debt reduction, leverage ratio <1.5x.
- **Tariffs**: $160K paid, with 2025 growth markets unaffected.

**Q&A Highlights**
- **Contract Expansion**: Largest customer requested 4-year contract extension with 2026+ volume commitments requiring $M+ capital investments in DR facilities.
- **Program Launches**: 2 new robotic surgery programs expected to scale to >$20M+ by 2027.
- **AJR Recovery**: Q4 2025 expected to reduce $8M Q3 backlog, with 2026+ gross margin normalization.
- **Acquisition Synergy**: 2025 acquisitions contributed $9M+ inorganic growth, with 2026 pipeline focused on MedTech adjacencies.


UFP Technologies, Inc. (UFPT) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: 37% Q2 growth driven by 46% medical segment expansion, including 567% jump from Stryker.
- **AJR Challenges**: $1.2M Q2 margin hit from labor turnover, escalating to $2.5M in Q3 before recovery in Q4.
- **Strategic Acquisitions**: UNIPEC and TPI enhance injection molding capabilities, with accretion expected in first year.
- **Dominican Expansion**: New facilities support RAS growth, with 7 active customers and 12 in development.
- **Customer Resilience**: Diversified product lines with top customers mitigate concentration risk, despite temporary supply chain adjustments.

**【CEO Summary Section】**
- **Q2 Revenue Growth**: 37% year-over-year, with 5% organic growth. Medical business surged 46%, including 7% growth in robotic-assisted surgery (RAS) and over 48% in patient services, interventional, and wound care.
- **Customer Performance**: Largest customers saw 10% growth (Intuitive Surgical) and 567% surge (Stryker). Advanced Components declined 20% as focus shifted to MedTech.
- **AJR Facility Challenges**: Labor turnover due to E-Verify audits caused $1.2M margin impact in Q2, expected $2.5M in Q3, with gradual recovery in Q4.
- **Acquisitions & Expansion**: Acquired UNIPEC and TPI for injection molding capabilities. Expanded Dominican Republic facilities to support RAS growth, with 7 active RAS customers and 12 in development.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP EPS $2.21, Non-GAAP EPS $2.50 (27% growth). Gross margin 28.8%, impacted by $1.2M AJR costs and $5M backlog. Q3 expects $7M revenue loss and $2.5M OI impact.
- **Tariffs & Costs**: Minimal direct tariff impact ($150k paid). Raw material inflation estimated at $9M annually, expected to be passed to customers.
- **Cash Flow & Debt**: $25.3M cash from operations, $19M debt reduction, leverage below 1.5x. Acquisitions expected to be accretive in first year.

**【Q&A Key Highlights】**
- **RAS Pipeline**: 7 active customers, 12+ in development, with revenue potential in next 1-2 years.
- **AJR Recovery**: Q3 low point for inefficiencies, with gradual improvement in Q4 as new hires gain experience.
- **Channel Inventory**: Destocking completed; Stryker inventory tight, requiring temporary reliance on alternative suppliers.
- **M&A Focus**: Injection molding acquisitions to enhance internal supply chain efficiency, with cultural and strategic fit prioritized.
- **Customer Diversification**: Top customers (Intuitive, Stryker) span multiple product lines, reducing concentration risk.

UFP Technologies, Inc. (UFPT) Q2 2025 Earnings Call Transcript

- **Revenue Surges 41%**: Medical segment dominates with 50% growth, led by safe patient handling ($29.2M Q1 vs. $19M annualized pre-acquisition). Robotic surgery decline temporary due to inventory adjustments.
- **DR Expansion Payoff**: New DR facilities and equipment position UFP to offset 10-20% price reductions through cost savings, with market growth maintaining revenue momentum.
- **Profitability Strong**: Adjusted EPS up 39.5% to $2.47, driven by operating leverage and cost control.
- **Tariff Resilience**: Minimal direct impact expected, with U.S.-based manufacturing (67% of revenue) providing competitive shield.
- **Growth Drivers**: Safe patient handling market growing ~20% annually, robotic surgery new programs launching H2 2025, and active M&A pipeline for med-tech adjacencies.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 2025 revenue increased 41% to $148.1 million, driven by 50% growth in the medical business, particularly the safe patient handling segment (now second-largest at $29.2M). Robotic surgery declined 6% due to inventory adjustments but remains a long-term growth driver with two new programs launching in H2 2025.
- **Acquisition Integration**: AJR's performance exceeded expectations, with $29.2M in Q1 revenue (vs. $19M annualized pre-acquisition). Exclusive manufacturing agreements in the Dominican Republic (DR) are expected to offset 10-20% price reductions through cost savings and market growth.
- **Strategic Expansion**: DR expansion includes a new 50,000 sq. ft. facility and R&D lab, supporting robotic surgery and safe patient handling growth. A small acquisition in St. Charles, IL added manufacturing capacity for the safe patient handling business.
- **Tariff Impact**: Management expects minimal direct impact from 10% tariffs on $8M in DR exports, with costs passed to customers. U.S.-based manufacturing (67% of revenue) provides competitive advantage.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted operating income rose 49.5% to $25.8M, with gross margin stable at 28.5%. Adjusted EPS increased 39.5% to $2.47, and adjusted EBITDA grew 45.9% to $30.2M.
- **Cash Flow**: Generated $13.8M in cash from operations, reducing debt to a leverage ratio below 1.5x. Capital expenditures were $2.8M, supporting DR expansion.
- **Tax Rate**: Q1 effective tax rate was 15.3%, with a normalized 21-23% guidance for 2025.

**【Q&A Highlights】**
- **Robotic Surgery Growth**: Largest customer expects low single-digit growth in 2025, with UFP maintaining ~67% share. New DR programs could add modest 2025 revenue and significant 2026+ contributions.
- **Competitive Position**: UFP's U.S. manufacturing base and DR expansion provide cost advantages over competitors reliant on Mexico or China. Safe patient handling market growth (~20% annually) offsets price reductions.
- **Acquisition Pipeline**: Actively pursuing small to mid-sized acquisitions in injection molding and med-tech adjacencies, with one large opportunity in early-stage discussions.
- **Geographic Expansion**: Exploring joint ventures in Asia-Pacific to support customer demand, while maintaining focus on DR and U.S. operations.


Actual									0.52	0.31	0.4	0.55	0.55	0.62	0.5	0.42	0.64	1.17	2.56	1.1	1.27	1.55	1.52	1.53	1.66	1.86	2.39	2.46	2.47	2.5	2.11	2.25
Forecast									0.54	0.2	0.32	0.415	0.36	0.52	0.59	0.405	0.45	0.74	0.945	0.895	1.12	1.42	1.5	1.12	1.165	1.54	1.86	2.135	2.01	2.25	2.1725	2.0683
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3.70%	+55.00%	+25.00%	+32.53%	+52.78%	+19.23%	-15.25%	+3.70%	+42.22%	+58.11%	+170.90%	+22.91%	+13.39%	+9.15%	+1.33%	+36.61%	+42.49%	+20.78%	+28.49%	+15.22%	+22.89%	+11.11%	-2.88%	+8.78%

UFPT

UFPT fundamentals

UFPT Q4 2025 Earnings

Earnings Call

You can ask Aime

UFPT

UFPT fundamentals

UFPT Q4 2025 Earnings

Earnings Call

UFPT Earnings Call Summary for Q4/20258:30 AM on Feb 25, 2026

UFPT Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

UFPT Earnings Call Summary for Q2/20258:30 AM on Aug 5, 2025

UFPT Earnings Call Summary for Q1/202510:00 AM on May 6, 2025

UFPT Earnings Call Summary for Q4/2024 Apr 5, 2026

You can ask Aime